

HOLDINGS LIMITED

The Directors are pleased to present the

# **Audited Financial Results for Padenga Holdings Limited**

For the year ended 31 December 2015

FINANCIAL HIGHLIGHTS		
	2015 US\$	2014 US\$
GROUP SUMMARY		
Revenue Operating profit before depreciation, impairment, amortisation	27 491 537	27 969 684
and fair value adjustments Profit before taxation Profit attributable to shareholders	9 985 704 9 950 207 7 255 523	8 723 234
Cash generated from operating activities Property, plant and equipment and intangible assets additions Net Assets	13 662 136 2 377 813 46 943 602	2 247 860
SHARE PERFORMANCE		
Basic earnings per share (cents) Dilutded earnings per share (cents) Dividend cover (times) Dividends declared and paid during the	1.34 1.34 4.6	1.11 1.11 6.9
year per share (cents) Market price per share (cents) Market capitalisation (US\$)	0.29 7.78 42 135 970	
Number of shares in issue at reporting date	541 593 440	541 593 440

### COMMENTARY

### FINANCIAL

The Group achieved excellent results which were, once again, a consequence of achieving the crocodile raw skin sales volume, further improving crocodile skin quality grades, producing the skin size profile requested by the customer, and coupled with stringent cost management within a challenging local

The Group recorded an operating profit before depreciation, amortisation, impairment and fair valuation adjustments of \$9,985,704 (\$9,952,056 – FY14) from turnover of \$27,491,537 in the twelve months to December 2015 compared to \$27,969,684 for the prior period to December 2014. Profit before tax was \$9.950.207 (\$8.723.234 - FY14).

Cash generated from operating activities more than doubled from \$5,408,147 for the period to December 2014 to \$13,662,136 in the period under review. This increase in cash generation was mainly attributed to an increased operating profit and a decrease in debtors of \$3,497,124. The decrease in debtors was a function of finishing culting earlier in the period under review and collecting the bulk of sales revenue before year-end. There was also a decrease in cultable biological assets (excluding fair value adjustments) by \$1,040,476 as we culled more crocodiles in the period under review

### **Crocodile Operation**

The flagship Zimbabwe crocodile operation, which accounts for 94% of turnover, had an outstanding year. Turnover increased by 7% to \$25,748,883 from \$24,079,194 recorded in the prior year to December 2014. The 46,025 contract skins sold in the current year represented an increase of 7% over the volumes in the previous period. Operating profit and profit before tax increased by 27% and 42% respectively to \$10,236,379 and \$11,430,874 against the operating profit of \$8,060,173 and a profit before tax of \$8,037,143 for the prior year. Headline Earnings Per Share for this unit was 1.6 cents.

### **Alligator Operation**

The United States Alligator operation recorded disappointing results in line with expectations. Disruptions to operations in this unit, previously reported on, contributed towards lower skin quality, lower skin volumes and depressed prices. The unit recorded turnover of \$1,742,654, this being a decrease of 55% compared to \$3,890,490 realised in the previous reporting period. Volumes were down 42% against prior period. (8,586 skins compared to 14,890 skins). Harvesting of some medium sized animals was deferred to 2016 in an attempt to improve the quality. The prices attained on skins sold were consequently lower than both budget and prior year. Approximately eight thousand skins harvested in December had not been graded or invoiced at year-end and sales for these skins will be recorded in 2016. The unit recorded an operating loss of \$236,866 and a loss before tax of \$346,782 compared to an operating profit of \$904,746 and a profit before tax of \$918,164 for the prior year

The Group increased its shareholding in Lone Star Alligator Farms from 50% to 67% following the withdrawal of one of the Members on 30 April 2015.

## OPERATIONS

## **Crocodile Operation**

In the crocodile operation 46,025 crocodiles were culled in the period under review which was an increase of 7% compared to both budget and prior period volumes. The skin quality grade achieved improved from 93% 1st Grades attained in 2014 to 96% in the period under review. Average skin size produced was consistent with our customer's requirements at 35.2cms, this being 1.5% down on the average size achieved in the prior year. We closed the period with a total of 161,572 grower crocodiles on the ground compared to 163,274 at the end of the prior period. The number of crocodiles on the ground is consistent with sustaining annual production at 46,000 skins. Forty new pens were constructed at Ume Farm to facilitate the earlier movement of crocodiles from hatchling pens in early summer each year and to further reduce overall stocking densities in an ongoing initiative to enhance welfare & to improve skin quality. Initiatives were taken to provide power backup solutions and to extend water pipelines on all farms in the event that Lake Kariba water levels drop to where the continued supply of

Demand for crocodile meat in Europe firmed during the period. Total meat volumes sold increased by 25% to 290 tonnes from 231 tonnes sold in the prior reporting period. However, the sales mix shifted towards low value cuts resulting in average prices reducing by 11%. Overall, meat turnover increased by

Notwithstanding the disappointing results achieved by this operation in the current year, management retains its confidence in this operation as evidenced by the increased shareholding and a recent management, technical and operational restructuring. The volume of alligators harvested in the period under review was 10% lower than budget. The breeder project was completed and stocked during the year and was rated by alligator biologists who have seen it to be a top class facility. Refinements were made to barns to allow for an increased pen water depth and for surface water bleed off to facilitate improved water quality at all times. Skinning and processing services were outsourced to allow maximum management focus on successful husbandry of the livestock and the production of quality skins.

### **PROSPECTS**

The fundamentals of the business remain sound. We have an excellent crop of crocodiles on the ground. Ongoing initiatives to further enhance animal welfare will contribute towards improved skin quality. Cash and working capital management is good. We anticipate another good year

The Board has declared a final dividend of 0.41 US cents per share, payable in respect of all the ordinary shares of the Company. This dividend is in respect of the financial year ending 31st December 2015 and will be payable in full to all the shareholders of the Company registered at the close of business on Friday ril 2016. The payment of this dividend will take place on or about Friday the 29th of April 2016 The shares of the Company will be traded cum - dividend on the Zimbabwe Stock Exchange up to the market day of Friday 8th April 2016 and ex - dividend as from Monday 11th April 2016. This dividend

### APPRECIATION

I would like to take this opportunity to thank the executive directors, management and staff for their commitment, initiative and work ethic in once again producing this excellent set of results within the current environment. I would also like to thank the non-executive directors for their continued support and wise counsel

### A K Calder Chairman 17 March 2016

### Consolidated Statement of Comprehensive Income

Revenue	For the twelve months ended 31 December 2015		
Revenue		31 Dec 2015	31 Dec 2014
Revenue		audited	audited
Other operating income		US\$	US\$
Net operating costs	Revenue	27 491 537	27 969 684
Departing profit before depreciation, impairment and amortisation   985 704   (1759 296)   (1622 205)   (16	Other operating income	46 213	46 120
Operating profit before depreciation, impairment and amortisation Depreciation and amortisation Impairment of goodwill Depreciation and amortisation Impairment of goodwill Gespansian State Stat	Net operating costs	(17 552 046)	(19 063 745)
Impairment of goodwill		9 985 704	8 952 059
Operating profit before interest and fair value adjustments         7 257 234         7 329 853           Fair value adjustments on biological assets         3 242 177         2 226 612           Profit before interest and tax         10 499 411         9 555 465           Interest payable         (857 109)         (959 505)           Interest payable         (857 109)         (959 505)           Profit before tax         9 950 208         8 723 234           Income tax expense         (2 864 790)         (2 270 032)           Profit for the year         7 085 418         6 453 202           Profit for the period attributable to:         7 085 418         6 453 202           Profit for the period attributable to:         2 7 085 418         6 453 202           Total comprehensive income for the year attributable to:         2 7 085 418         6 453 202           Total comprehensive income for the year attributable to:         2 255 522         6 004 870           Equity holders of the parent         7 255 523         6 004 870           Non-controlling interest         7 255 523         6 004 870           Non-controlling interest         7 085 418         6 453 202           Equity holders of the parent         7 255 523         6 004 870           Non-controlling interest         7 085	Depreciation and amortisation	(1 759 296)	(1 622 206)
Fair value adjustments on biological assets 7 226 612 Profit before interest and tax 10 499 411 9 5556 435 Interest income 10 307 906 116 305 Interest payable 10 87 7095 116 99 950 208 126 305 Interest payable 10 99 950 208 127 3234 Income tax expense 10 2864 790) 10 2 270 032) Profit for the year 10 2 70 85 418 10 453 202 Profit or the period attributable to: Equity holders of the parent 10 448 332 10 20 20 20 20 20 20 20 20 20 20 20 20 20	Impairment of goodwill	(969 174)	· - '
Profit before interest and tax         10 499 411         9 556 465           Interest income         307 906         (857 109)         (959 536)           Profit before tax         9 950 208         8 723 234         (2 270 32)           Income tax expense         (2 864 790)         (2 270 32)         (2 270 32)           Profit for the year         7 085 418         6 453 202           Other comprehensive income         7 085 418         6 453 202           Profit for the period attributable to:         2 200 40 870         40 870           Equity holders of the parent         7 255 522         6 004 870           Non-controlling interest         (170 104)         448 332           Total comprehensive income for the year attributable to:         2 55 523         6 004 870           Equity holders of the parent         7 255 523         6 004 870           Non-controlling interest         7 255 523         6 004 870           Non-controlling interest         7 255 523         6 004 870           Equity holders of the parent         7 255 523         6 004 870           Non-controlling interest         7 085 418         6 453 202			
Interest income			
Interest payable	Profit before interest and tax		
Profit before tax         950 208         8 723 234           Income tax expense         (2 864 790)         (2 270 332)           Profit for the year         7 085 418         6 453 202           Other comprehensive income         7 085 418         6 453 202           Profit for the period attributable to:         2         6 004 870           Equity holders of the parent         7 255 522         6 004 870           Non-controlling interest         7 085 418         6 433 202           Total comprehensive income for the year attributable to:         Equity holders of the parent         7 255 523         6 004 870           Non-controlling interest         (170 105)         448 332           Non-controlling interest         7 085 418         6 453 202           Earnings per share (cents)         3 085 418         6 453 202           Basic earnings per share         1.34         1.11           Diluted earnings per share         1.34         1.11			
Income tax expense   (2 864 790)   (2 270 032)     Profit for the year   7 085 418   6 453 202     Total comprehensive income for the year   7 085 418   6 453 202     Total comprehensive income for the year   7 085 418   6 453 202     Profit for the period attributable to:   2			
Profit for the year         7 085 418         6 453 202           Other comprehensive income         7 085 418         6 453 202           Total comprehensive income for the year         7 085 418         6 453 202           Profit for the period attributable to:         7 255 522         6 004 870           Equity holders of the parent         (170 104)         448 332           Total comprehensive income for the year attributable to:         6 453 202           Equity holders of the parent         7 255 523         6 004 870           Non-controlling interest         (170 105)         448 332           Formula of the parent interest         7 085 418         6 453 202           Earnings per share (cents)         8 32         7 085 418         6 453 202           Basic earnings per share         1.34         1.11           Diluted earnings per share         1.34         1.11			
Comprehensive income			
Total comprehensive income for the year   7 085 418   6 453 202		7 085 418	6 453 202
Profit for the period attributable to:         7 255 522         6 004 870           Equity holders of the parent         (170 104)         448 332           Non-controlling interest         7 085 418         6 453 202           Total comprehensive income for the year attributable to:         7 255 523         6 004 870           Equity holders of the parent         7 255 523         6 004 870           Non-controlling interest         (170 105)         448 332           Earnings per share (cents)         7 085 418         6 453 202           Basic earnings per share         1.34         1.11           Diluted earnings per share         1.34         1.11		-	
Equity holders of the parent Non-controlling interest     7 255 522 (170 104)     6 004 870 (170 104)     448 332 (170 104)     448 332 (170 104)     7 085 418     6 453 202 (170 105)     6 004 870 (170 105)     448 332 (170 105)     6 004 870 (170 105)     448 332 (170 105)     448 332 (170 105)     448 332 (170 105)     6 453 202 (170 105)     6 453 202 (170 105)     6 453 202 (170 105)     6 13 202 (170 105		7 085 418	6 453 202
Non-controlling interest         (170 104) 7085 418         448 332 6 453 202           Total comprehensive income for the year attributable to: Equity holders of the parent Non-controlling interest         7 255 523 (170 105) 448 332 7 085 418         6 004 870 6 453 202           Earnings per share (cents) Basic earnings per share         1.34 1.11         1.11           Diluted earnings per share         1.34 1.11         1.11			
Total comprehensive income for the year attributable to:   Equity holders of the parent   7 255 523   6 004 870     Non-controlling interest   (170 105)   448 332     Total comprehensive income for the year attributable to:   Equity holders of the parent   (170 105)   448 332     Total comprehensive   7 255 523   6 004 870     448 332   7 085 418   6 453 202     Earnings per share (cents)   8 2			
Total comprehensive income for the year attributable to:   Equity holders of the parent Non-controlling interest (170 105) 448 332 7085 418 6453 202     Earnings per share (cents)     Basic earnings per share   1.34 1.11     Diluted earnings per share   1.34 1.11	Non-controlling interest		
Equity holders of the parent Non-controlling interest     7 255 523 (170 048 70 0		7 085 418	6 453 202
Non-controlling interest         (170 105) 7 085 418         448 332 6 453 202           Earnings per share (cents) Basic earnings per share         1.34         1.11           Diluted earnings per share         1.34         1.11		7.055.500	0.004.070
Earnings per share (cents)         7 085 418         6 453 202           Basic earnings per share         1.34         1.11           Diluted earnings per share         1.34         1.11			
Earnings per share (cents)         1.34         1.11           Basic earnings per share         1.34         1.11           Diluted earnings per share         1.34         1.11	Non-controlling interest		
Basic earnings per share         1.34         1.11           Diluted earnings per share         1.34         1.11		7 085 418	6 453 202
Diluted earnings per share 1.34 1.11		4.04	4.44
5.00			
Consolidated Statement of Financial Position	Diluted earnings per snare	1.34	1.11
	Consolidated Statement of Financial Position		

Consolidated Statement of Financial Position		
As at 31 December 2015		
	31 Dec 2015 audited US\$	31 Dec 2014 audited US\$
ASSETS	03\$	03\$
Non-current assets		
Property, plant and equipment Goodwill	15 223 986	14 730 118 969 174
Intangible assets	51 796	63 998
Biological assets	3 686 179	2 206 960
Current assets	18 961 961	17 970 250
Biological assets	26 149 950	25 298 882
Inventories	3 523 179 2 482 402	2 416 917
Trade and other receivables Cash and cash equivalents	10 525 248	5 979 525 2 392 817
•	42 680 779	36 088 142
Total assets	61 642 740	54 058 392
EQUITY AND LIABILITIES		
Capital and reserves	54.450	54.450
Share capital Share premium	54 159 27 004 245	54 159 27 004 245
Retained earnings	19 421 793	13 760 273
Change in ownership reserve	(165 948)	- 40.040.077
Equity attributed to equity holders of the parent Non- controlling interest	<b>46 314 249</b> 629 353	<b>40 818 677</b> 1 113 509
Total shareholders' equity	46 943 602	41 932 186
Non-current liabilities	2 321 833	991 705
Long-term interest bearing borrowings Customer deposits	1 130 525	1 194 615
Deferred tax liabilities	6 206 596	5 309 189
Current liabilities	9 658 954	7 495 509
Short-term interest bearing borrowings	1 334 671	1 568 135
Deferred consideration	1 366 770	831 680
Trade and other payables	1 733 070	1 406 951

## Total liabilities Total equity and liabilities Consolidated Statement of Changes in Equity

Provisions Current tax payable

For the twelve months ende	Share		Change in ownership	Retained	(	Non - Controllina	
	Capital audited US\$	Premium audited US\$	Reserve audited US\$	Earnings audited US\$	Total US\$	Interest audited US\$	Total audited US\$
Balance at 1 January 2014	54 159	27 004 245	-	8 610 518	35 668 922	821 525	36 490 447
Profit for the year Dividends paid	-	-	-	6 004 870 (855 115)	6 004 870 (855 115)	448 332	6 453 202 (855 115)
Dividends paid by subsidiary  Balance at 31 December 2014	54 159	27 004 245	- :	13 760 273	40 818 677	(156 348) 1 113 509	(156 348) 41 932 186

For the twelve months ended 3	Decem	per 2015					
	Share	Share	Change in ownership	Retained	(	Non - Controlling	
	Capital audited	Premium audited	Reserve audited	Earnings audited	Total	Interest	Total audited
	US\$	US\$	US\$	US\$	US\$	US\$	US\$
Balance at 1 January 2015	54 159	27 004 245	-	13 760 273	40 818 677	1 113 509 4	11 932 186
Profit for the year	-	-	-	7 255 522	7 255 522	(170 104)	7 085 418
Acquisition of non-controlling inte	rest -	-	(165 948)	-	(165 948)	$(314\ 052)$	(480 000)
Dividends paid	-	-		(1 594 002)	(1 594 002)	- '	(1 594 002)
Balance at 31 December 2015	54 159	27 004 245	(165 948)	19 421 793	46 314 249	629 353 4	6 943 602

Consolidated Statement of Cash Flows		
For the twelve months ended 31 December 2015		
	31 Dec 2015	31 Dec 2014
	audited US\$	audited US\$
Cash generated from operating activities	13 662 136	5 408 147
Interest income	307 906	126 305
Interest paid	(786 416)	(858 300)
Taxation paid Net cash generated from operations	(2 <sup>2</sup> 33 289) 10 950 337	<u>(1 116 689)</u> <b>3 559 463</b>
Cash flow from investing activities	10 330 337	3 333 403
Net cash outflow from investing activities	(2 375 834)	(2 155 762)
Net cash flow before financing activities	8 574 503	1 403 701
Cash flow from financing activities Increase/(decrease) in borrowings	1 151 930	(8 268 392)
- new loans	13 604 865	5 775 000
- repayments	(12 452 935)	(14 043 392)
Dividends paid	(1 594 002)	(1 011 463)
by holding company	(1 594 002)	(855 115)
by subsidiaries to non-controlling shareholders	-	(156 348)
Net cash flow utilised in financing activities	(442 075)	(9 279 855)
Net increase / (decrease) in cash and cash equivalents	8 132 431	(7 876 154)
Cash and cash equivalents at the beginning of the period	2 392 817	10 268 970
Cash and cash equivalents at the end of the period	10 525 248	2 392 817
CASH AND CASH EQUIVALENTS		
Made up as follows:		
Bank balances and cash	8 425 083	2 391 013
Short-term investments	2 100 165 10 525 248	2 392 817
	10 323 240	2 332 017

## Directors' responsibility

Directors responsibility

The company's directors are responsible for the preparation and fair presentation of the Group's financial statements, of which this press release represents an extract. The financial statements have been prepared in accordance with International Financial Reporting Standards and in the manner required by the Companies' Act (Chapter 24.03). The principal accounting policies of the Group are consistent with those applied in the previous year except that the Group measured its breeder biological assets at fair value in the current year as the Group was able to determine the fair value reliably.

## Audit statement

These condensed financial results must be read in conjunction with the complete set of financial statements for the year ended 31 December 2015, which have been audited by Ernst & Young and an unmodified audit opinion issued thereon. The auditor's report on these financial results is available for inspection at the company's registered office.

## Corporate Information

Corporate Information
Padenga Holdings Limited is a Limited Liability Company incorporated and domiciled in Zimbabwe whose shares are publicly traded on the Zimbabwe Stock exchange. The Group has a 67% stake in Lone Star Alligator Farms, an unlisted company based in Texas (United States of America) that specializes in alligator farming. The principal activity of the Company and its subsidiaries (the Group) include the production and rearing of crocodiles, alligators and the export of Nile crocodile and alligator skins and meat.

### Supplementary Information

### Basis of preparation

The financial results are based on the statutory records that are maintained under the historical cost basis, except for biological assets that have been measured at fair value.

### Statement of compliance

The Group's abridged financial results have been prepared in accordance with ZSE listing rules. The financial statements have been prepared in compliance with the Zimbabwe Companies Act

**Currency of reporting**The financial results are expressed in United States Dollars which is the Group's presentation and

### 7.

Parametes When preparing the interim financial results, management undertakes a number of judgements, estimates and assumptions about recognition and measurement of assets, results, liabilities, income and expenses. The actual results may differ from the judgements, estimates and assumptions made by management, and will seldom equal the estimated results.

The judgements, estimates and assumptions applied in the interim financial statements, including the key sources of estimation uncertainty were the same as those applied in the Group's last annual financial statements for the year ended 31 December 2014.

Accounting policies
The principal accounting policies of the Group are consistent in all material respects with those applied in the previous financial year and conform with all effective IFRS as at 31 December 2015

Operating segments
The following tables present revenue and profit information about the Group's operating segments for the twelve months ended 31 December 2015.

	Crocodiles US\$	Alligators US\$	Adjustments & eliminations US\$	Consolidated US\$
Revenue 31 December 2015 31 December 2014	25 748 883 24 079 194	1 742 654 3 890 490	-	27 491 537 27 969 684
Operating Profit/(loss) befor adjustments	e impairmen	t, depreciation	n, amortization	and fair value
31 December 2015 31 December 2014	10 236 379 8 060 173	(250 675) 891 886		9 985 704 8 952 059
Depreciation and amortization				
31 December 2015 31 December 2014	1 617 013 1 483 777	142 283 138 429	-	1 759 296 1 622 206
Interest Expense				
31 December 2015 31 December 2014	571 009 602 711	286 100 356 825	-	857 109 959 536
Profit/(loss) before tax				
31 December 2015 31 December 2014	11 430 874 8 037 143	(511 493) 843 105	(969 174) (156 814)	9 950 207 8 723 234
Segment assets				
31 December 2015 31 December 2014	54 666 761 47 190 513	6 975 979 6 867 878	-	61 642 740 54 058 391
Segment liabilities				
31 December 2015 31 December 2014	7 414 433 6 824 667	7 591 181 5 109 385	(306 476) 192 153	14 699 138 12 126 205
Capital expenditure (property,	plant & biolo	gical assets)		
31 December 2015 31 December 2014	1 903 475 1 753 685	474 338 494 175	-	2 377 813 2 247 860
Classification of the segments is	based on the	type of biologica	l assets.	

Revenue from one customer amounted to \$26 401 809 (2014: \$26 609 487), arising from sales of

10.	Capital expenditure for the year Capital expenditure commitment	31 Dec 2015 US\$ 2 377 813	31 Dec 2014 US\$ 2 247 860
	Authorized but not yet contracted	2 454 480 2 454 480	1 908 258 1 908 258
11.	Future lease commitments Payable within one year Payable between two and five years Payable after five years	192 360 512 235 468 500 1 173 095	185 235 435 735 250 500 871 470
	The capital expenditure will be financed from the Group's own resources and borrowing facilities.		
12. 12.1	Trade and other payables Trade Accruals Sundry creditors Customer deposits	358 858 1 367 903 6 309 1 733 070	240 796 1 164 033 2 122 1 406 951
	1 Non-Current Customer deposits	1 130 525	1 194 615

Customer deposits mainly relate to advances received from our main customer to fund the operations of the foreign entity. This will be settled through delivery of hatchlings starting in 2017.

## 13. Interest bearing loans and borrowings 13.1 Non-Current interest bearing loans and bo

13.1	Non-Current interest bearing loans and b			
		Year repayable		
	Unsecured	. ,		
	Foreign long term borrowings	2018	2 321 833	991 705
			2 321 833	991 705
13 2	Current interest bearing loans and borro	winge	2 02 1 000	
10.2	Current interest bearing loans and borro	Year repayable		
		(March 2016)		
	0	(Watch 2010)		
	Secured		4 00 4 074	4 500 405
	Foreign short term borrowings	up to -90days	1 334 671	<u>1 568 135</u>
			1 334 671	<u>1 568 135</u>
13.3	Deferred consideration			
		Year repayable		
	Current			
	Deferred consideration	December 2016	1 366 770	831 680
	Reconciliation			
	Financial liability		831 680	843 671
	Interest		168 321	101 240
	Acquisition of non-controlling interest		480 000	101 240
	Payments		(113 231)	(113 231)
	Balance		1 366 770	831 680

The financial liability at fair value relates to deferred consideration discounted at 12% (fixed rate) market related rate in the United States of America and payable in year 3. There were no restrictions noted in the companies act with regards to this transaction.

Short term borrowings form part of the core borrowings of the Group and are renewed on maturity Short term borrowings form part of the core borrowings of the croup and are renewed on maturity in terms of on-going facilities negotiated with the relevant financial institutions. The facility is secured by first charge over certain of the Group's fixed assets, book debts and biological assets with a carrying value of \$10,00,000. The Group has a short term facility of \$11,600,000, rate of interest for local operations is 7%-10% whilst for the foreign operation ranges from 6%-12%. The facility was utilized at the end of the reporting period.

## **Borrowing Powers**

In terms of the Company's Articles of Association, the Group may, with previous sanction of an ordinary resolution of the company in a general meeting, borrow, on the determination of the Directors, amounts that do not exceed the aggregate total equity.

## Increase in shareholding in Lone Star Alligator Farms

The group increased its shareholding in Lone Star Alligator Farms from 50% to 67% following the withdrawal of one of the members on 30 April 2015.

## 15.

Earnings per share
Basic earnings basis
The calculation is based on the profit attributable to equity holders of the parent and the weighted average number of ordinary shares in issue for the year

Fully diluted earnings basis
The calculation is based on the profit attributable to equity holders of the parent and the weighted average number of ordinary shares in issue after adjusting to assume conversion of share options not yet exercised and convertible instruments. There were no instruments with a dilutive effect at

## 16.

Contingent liabilities
The Group had no contingent liabilities at 31 December 2015.

## 17.

Events after reporting period
There were no adjusting or non-adjusting events after the reporting date at the time of issuing these
financial results.